News
10/30/2026
Emily Estrada
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include cosibelimab as a Category 2A recommended treatment option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation, supported by clinical...
Updated NCCN guidelines include...
10/30/2026
Oncology
News
10/01/2026
Emily Estrada
Results from the retrospective, real-world TOSCA trial demonstrated that cemiplimab improved overall and progression-free survival compared with historical systemic therapies in patients with locally advanced or metastatic cutaneous squamous...
Results from the retrospective, real-world TOSCA trial demonstrated that cemiplimab improved overall and progression-free survival compared with historical systemic therapies in patients with locally advanced or metastatic cutaneous squamous...
Results from the retrospective,...
10/01/2026
Oncology
News
10/01/2026
Emily Estrada
A retrospective trial found that definitive cemiplimab monotherapy provided durable disease control in selected patients with locally advanced, resectable head and neck cutaneous squamous cell carcinoma, supporting further evaluation of PD-1...
A retrospective trial found that definitive cemiplimab monotherapy provided durable disease control in selected patients with locally advanced, resectable head and neck cutaneous squamous cell carcinoma, supporting further evaluation of PD-1...
A retrospective trial found that...
10/01/2026
Oncology
News
08/28/2026
Emily Estrada
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study...
08/28/2026
Oncology
News
08/28/2026
Emily Estrada
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi...
08/28/2026
Oncology
News
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
Quiz
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
News
02/04/2026
Stephanie Holland
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary analysis of the phase 3 TROG 05.01 trial identified a subgroup of patients with high-risk cutaneous squamous cell carcinoma of the head and neck who experienced significantly worse survival following postoperative...
Results from a secondary...
02/04/2026
Oncology
Quiz
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
News
01/29/2026
Stephanie Holland
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide, population-based study demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ increased steadily over nearly two decades, highlighting the growing burden...
Results from a nationwide,...
01/29/2026
Oncology
FDA Approval
10/08/2025
Allison Casey
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab for the adjuvant treatment of patients with cutaneous squamous cell carcinoma who are at high risk for recurrence following surgery and radiation.
The US FDA approved cemiplimab...
10/08/2025
Oncology
